Relationship Between BRAF V600E Alone, TERT Promoter Mutation Alone, or Their Coexistence and Loss of Radioiodine Avidity in Recurrent PTC
| Loss of RAI | Odds ratio | |||
| Tumor type and mutation status | n | P | Unadjusted | Adjusted* |
| All PTC | ||||
| No mutation | 16/53 (30.2) | Reference | 1.00 | 1.00 |
| BRAF V600E alone | 45/64 (70.3) | <0.001 | 5.39 (2.31–13.13) | 4.92 (2.07–12.20) |
| TERT mutation alone | 5/9 (55.6) | 0.251 | 2.84 (0.53–16.32) | 2.10 (0.28–16.51) |
| BRAF + TERT mutations | 37/38 (97.4) | <0.001 | 81.04 (11.67–3,559.83) | 103.68 (10.77–5,771.67) |
| CPTC | ||||
| No mutation | 8/36 (22.2) | Reference | 1.00 | 1.00 |
| BRAF V600E alone | 39/55 (70.9) | <0.001 | 8.30 (2.93–25.95) | 7.33 (2.54–23.34) |
| TERT mutation alone | 2/3 (66.7) | 0.156 | 6.57 (0.31–427.22) | 20.44 (0.22–2,768.33) |
| BRAF + TERT mutations | 32/32 (100.00) | <0.001 | 136.12 (20.82–+∞) | 179.58 (20.97–+∞) |
↵* Adjusted for patient age and sex.
CPTC = conventional PTC.
TERT promoter mutations here included, collectively, TERT C228T and TERT C250T. Data in parentheses are percentages or 95% CIs.